Improvement in β-Cell Secretory Capacity After Human Islet Transplantation According to the CIT07 Protocol

The Clinical Islet Transplantation 07 (CIT07) protocol uses antithymocyte globulin and etanercept induction, islet culture, heparinization, and intensive insulin therapy with the same low-dose tacrolimus and sirolimus maintenance immunosuppression as in the Edmonton protocol. To determine whether CIT07 improves engrafted islet β-cell mass, our center measured β-cell secretory capacity from glucose-potentiated arginine tests at days 75 and 365 after transplantation and compared those results with the results previously achieved by our group using the Edmonton protocol and normal subjects. All subjects were insulin free, with CIT07 subjects receiving fewer islet equivalents from a median of one donor compared with two donors for Edmonton protocol subjects. The acute insulin response to glucose-potentiated arginine (AIRpot) was greater in the CIT07 protocol than in the Edmonton protocol and was less in both cohorts than in normal subjects, with similar findings for C-peptide. The CIT07 subjects who completed reassessment at day 365 exhibited increasing AIRpot by trend relative to that of day 75. These data indicate that engrafted islet β-cell mass is markedly improved with the CIT07 protocol, especially given more frequent use of single islet donors. Although several peritransplant differences may have each contributed to this improvement, the lack of deterioration in β-cell secretory capacity over time in the CIT07 protocol suggests that low-dose tacrolimus and sirolimus are not toxic to islets.

[1]  M. Rickels Recovery of Endocrine Function After Islet and Pancreas Transplantation , 2012, Current Diabetes Reports.

[2]  Nicole A. Turgeon,et al.  Improvement in Outcomes of Clinical Islet Transplantation: 1999–2010 , 2012, Diabetes Care.

[3]  B. Hering,et al.  Potent Induction Immunotherapy Promotes Long‐Term Insulin Independence After Islet Transplantation in Type 1 Diabetes , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  S. Paraskevas,et al.  Evidence of Endoplasmic Reticulum Stress Mediating Cell Death in Transplanted Human Islets , 2012, Cell transplantation.

[5]  M. Rickels,et al.  Accumulation of intrahepatic islet amyloid in a nonhuman primate transplant model. , 2012, Endocrinology.

[6]  M. Rickels,et al.  Hypersensitivity to rabbit antithymocyte globulin in an islet transplant recipient: a case report. , 2011, Transplantation proceedings.

[7]  C. Ricordi,et al.  Correction of insulin sensitivity and glucose disposal after pancreatic islet transplantation: preliminary results , 2010, Diabetes, obesity & metabolism.

[8]  T. Berney,et al.  Glucose inhibits angiogenesis of isolated human pancreatic islets. , 2010, Journal of molecular endocrinology.

[9]  M. Rickels,et al.  HLA Class I Sensitization in Islet Transplant Recipients: Report from the Collaborative Islet Transplant Registry 1 , 2010, Cell transplantation.

[10]  T. Berney,et al.  Influence of Donor Age on Islet Isolation and Transplantation Outcome , 2010, Transplantation.

[11]  B. Hering,et al.  Erratum: Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes(American Journal of Transplantation (2009) 8 (2463-2470) DOI: 10.1111/j.1600-6143.2008.02404.x ) , 2010 .

[12]  M. Rickels,et al.  {beta}-Cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants. , 2010, The Journal of clinical endocrinology and metabolism.

[13]  A. Shapiro,et al.  Insulin-Heparin Infusions Peritransplant Substantially Improve Single-Donor Clinical Islet Transplant Success , 2010, Transplantation.

[14]  A Sundin,et al.  Positron Emission Tomography in Clinical Islet Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  B. Hering,et al.  Prolonged Insulin Independence After Islet Allotransplants in Recipients with Type 1 Diabetes , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  S. Kahn,et al.  An examination of β‐cell function measures and their potential use for estimating β‐cell mass , 2008, Diabetes, obesity & metabolism.

[17]  M. Rickels,et al.  Acute insulin responses to glucose and arginine as predictors of beta-cell secretory capacity in human islet transplantation. , 2007, Transplantation.

[18]  R. Robertson Estimation of β-Cell Mass by Metabolic Tests , 2007, Diabetes.

[19]  M. Rickels,et al.  Evidence for allograft rejection in an islet transplant recipient and effect on beta-cell secretory capacity. , 2007, The Journal of clinical endocrinology and metabolism.

[20]  Philippe Morel,et al.  International trial of the Edmonton protocol for islet transplantation. , 2006, The New England journal of medicine.

[21]  B. Hering,et al.  Intrahepatic Transplanted Islets in Humans Secrete Insulin in a Coordinate Pulsatile Manner Directly Into the Liver , 2006, Diabetes.

[22]  M. Rickels,et al.  Insulin sensitivity, glucose effectiveness, and free fatty acid dynamics after human islet transplantation for type 1 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.

[23]  B. Hering,et al.  Effect of Donor Age on Function of Isolated Human Islets , 2006, Diabetes.

[24]  B. Hering,et al.  Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. , 2005, JAMA.

[25]  T. Berney,et al.  Assessment of a Novel Two-Component Enzyme Preparation for Human Islet Isolation and Transplantation , 2005, Transplantation.

[26]  G. Elgue,et al.  TISSUE FACTOR RELEASED BY THE ENDOCRINE CELLS OF THE ISLETS OF LANGERHANS IS ASSOCIATED WITH A NEGATIVE OUTCOME OF CLINICAL ISLET TRANSPLANTATION , 2004, Diabetes.

[27]  T. Berney,et al.  Serva collagenase NB1: a new enzyme preparation for human islet isolation. , 2004, Transplantation proceedings.

[28]  D. Harlan,et al.  Sirolimus-induced interstitial pneumonitis in an islet transplant recipient. , 2003, Diabetes care.

[29]  B. Wolf,et al.  Insulin Independence Following Isolated Islet Transplantation and Single Islet Infusions , 2003, Annals of surgery.

[30]  K. Ekdahl,et al.  Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation , 2002, The Lancet.

[31]  D. D’Alessio,et al.  Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. , 2002, Diabetes.

[32]  B. Ahrén,et al.  Glucose-dependent arginine stimulation test for characterization of islet function: studies on reproducibility and priming effect of arginine , 1998, Diabetologia.

[33]  C. Ricordi,et al.  Improved Human Islet Isolation Using a New Enzyme Blend, Liberase , 1997, Diabetes.

[34]  D. Finegood,et al.  The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients. , 1996, Transplantation.

[35]  G. Warnock,et al.  Cytotoxic effects of cytokines on human pancreatic islet cells in monolayer culture. , 1990, The Journal of clinical endocrinology and metabolism.

[36]  J. Markmann,et al.  THE EFFECT OF ISLET CELL CULTURE IN VITRO AT 24°C ON GRAFT SURVIVAL AND MHC ANTIGEN EXPRESSION , 1990 .

[37]  P. Lacy,et al.  Automated Islet Isolation From Human Pancreas , 1989, Diabetes.

[38]  R. Strieter,et al.  Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxofylline , 1988 .

[39]  G. Eisenbarth,et al.  Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. , 1985, Diabetes research.

[40]  J. Halter,et al.  Adaptation of B and A cell function during prolonged glucose infusion in human subjects. , 1984, The American journal of physiology.

[41]  Joan W. Miller,et al.  Long-Term Results of Rabbit Antithymocyte Globulin and Basiliximab Induction , 2008 .

[42]  R. Robertson Estimation of beta-cell mass by metabolic tests: necessary, but how sufficient? , 2007, Diabetes.

[43]  M. Rickels,et al.  HLA sensitization in islet transplantation. , 2006, Clinical transplants.

[44]  Michael R. Rickels,et al.  β-Cell Function Following Human Islet Transplantation for Type 1 Diabetes , 2005 .

[45]  Ames,et al.  Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen , 2000 .

[46]  M. Field,et al.  Inhibition of pancreatic islet beta cell function by tumor necrosis factor is blocked by a soluble tumor necrosis factor receptor. , 1993, Transplantation proceedings.

[47]  C. Ricordi,et al.  Abnormal sensitivity to glucose of human islets cultured in a high glucose medium: partial reversibility after an additional culture in a normal glucose medium. , 1991, The Journal of clinical endocrinology and metabolism.

[48]  J. Markmann,et al.  The effect of islet cell culture in vitro at 24 degrees C on graft survival and MHC antigen expression. , 1990, Transplantation.

[49]  R. Strieter,et al.  Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. , 1988, Biochemical and biophysical research communications.

[50]  L. Mandarino,et al.  Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. , 1982, The Journal of clinical endocrinology and metabolism.